General
Preferred name
PRETOMANID
Synonyms
(S)-PA 824 ()
PA-824 ()
Pretomanid (PA-824) ()
PA824 ()
PA 824 ()
P&D ID
PD008643
CAS
187235-37-6
Tags
available
drug
Approved by
EMA
FDA
First approval
2019
Drug Status
approved
Drug indication
Tuberculosis
Mycobacterium infection
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Pretomanid is a nitroimidazole-based antibacterial used for the treatment of multi-drug-resistant pulmonary tuberculosis . It is active against replicating and non-replicating Mycobacterium tuberculosis . Pretomanid was developed by the non-profit organisation TB Alliance (www.tballiance.org.za).
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
0
Organisms
9
Compound Sets
19
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
Pandemic Response Box
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Pathogen Box
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
29
Molecular Weight
359.07
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
0
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
2
cLogP
2.67
TPSA
88.65
Fraction CSP3
0.36
Chiral centers
1.0
Largest ring
6.0
QED
0.6
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Disease
TUBERCULOSIS
Pathway
Microbiology&virology
Anti-infection
Target
tuberculosis
FASN
antibiotic
Bacterial
MOA
Nitric oxide donor
Source data
